

Appendix C: Results of the stage III/IV subgroup analyses

Table C.1

Constant hazard ratio estimates^a from a fixed-effects network meta-analysis of recurrence-free/disease-free survival in patients with resected stage III/IV melanoma.

Observation or placebo	1.94 (1.50, 2.49)	2.04 (1.68, 2.48)	1.79 (1.46, 2.19)	1.32 (1.11, 1.55)	1.31 (1.00, 1.72)	1.15 (0.95, 1.40)	1.11 (1.01, 1.22)
0.52 (0.40, 0.67)	Nivolumab	1.06 (0.77, 1.46)	0.92 (0.67, 1.28)	0.68 (0.56, 0.82)	0.68 (0.51, 0.90)	0.60 (0.43, 0.82)	0.57 (0.44, 0.75)
0.49 (0.40, 0.60)	0.95 (0.69, 1.30)	Dabrafenib + trametinib	0.87 (0.66, 1.16)	0.65 (0.50, 0.83)	0.64 (0.46, 0.90)	0.56 (0.43, 0.75)	0.54 (0.44, 0.68)
0.56 (0.46, 0.69)	1.08 (0.78, 1.50)	1.15 (0.86, 1.51)	Pembrolizumab	0.74 (0.57, 0.96)	0.74 (0.53, 1.04)	0.65 (0.49, 0.86)	0.62 (0.50, 0.78)
0.76 (0.65, 0.90)	1.47 (1.22, 1.78)	1.55 (1.21, 2.00)	1.36 (1.04, 1.76)	Ipilimumab 10 mg/kg	1.00 (0.81, 1.24)	0.88 (0.67, 1.14)	0.84 (0.70, 1.03)
0.76 (0.58, 1.00)	1.47 (1.11, 1.96)	1.55 (1.11, 2.17)	1.36 (0.96, 1.90)	1.00 (0.81, 1.24)	Ipilimumab 3 mg/kg	0.88 (0.63, 1.24)	0.84 (0.63, 1.13)
0.87 (0.72, 1.05)	1.68 (1.22, 2.31)	1.77 (1.34, 2.33)	1.55 (1.16, 2.06)	1.14 (0.88, 1.48)	1.14 (0.81, 1.60)	Other chemotherapy	0.96 (0.80, 1.15)
0.90 (0.82, 0.99)	1.74 (1.33, 2.28)	1.84 (1.48, 2.28)	1.61 (1.28, 2.02)	1.19 (0.97, 1.44)	1.19 (0.88, 1.59)	1.04 (0.87, 1.25)	IFN pooled

^aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatment indicated in that row versus the treatment indicated in that column; bolded values are statistically significant at the 0.05 significance level.

IFN: interferon.

Table C.2

Constant hazard ratio estimates^a from a fixed-effects network meta-analysis of distant metastasis-free survival in patients with stage III/IV melanoma.

Observation or placebo	1.69 (1.26, 2.24)	1.89 (1.49, 2.37)	1.32 (1.11, 1.56)	1.06 (0.94, 1.20)
0.59 (0.45, 0.79)	Nivolumab	1.12 (0.77, 1.62)	0.78 (0.62, 0.98)	0.63 (0.46, 0.86)
0.53 (0.42, 0.67)	0.90 (0.62, 1.29)	Dabrafenib + trametinib	0.70 (0.52, 0.94)	0.56 (0.43, 0.73)
0.76 (0.64, 0.90)	1.28 (1.02, 1.61)	1.43 (1.07, 1.91)	Ipilimumab 10 mg/kg	0.81 (0.65, 1.00)
0.94 (0.83, 1.06)	1.60 (1.16, 2.17)	1.78 (1.36, 2.31)	1.24 (1.00, 1.53)	IFN pooled

^aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatment indicated in that row versus the treatment indicated in that column; bolded values are statistically significant at the 0.05 significance level.

IFN: interferon.